NJ Bio, Inc., has been awarded the prestigious Best Contract Research Organization (CRO) title at the 11th Annual World ADC Awards in San Diego, marking the company’s fourth consecutive win. This successive win underscores NJ Bio’s commitment and the continued trust of its clients and collaborators.
The consecutive wins have fueled the team’s drive for excellence, reflected in the organization’s significant growth over the past few years, as it advances capabilities and continuously improves services to meet the needs of clients. NJ Bio has evolved from a dedicated CRO into a CDMO offering GMP-compliant support for early-phase clinical trials. It has expanded its technical capabilities significantly, building a cutting-edge analytical platform by investing in advanced instrumentation. The company has built a team of highly skilled scientists with deep expertise in tackling complex drug development projects.
This year’s win reaffirms their dedication to innovation and quality, as the organization continually advances its service offerings to support every phase of the drug development process. Achieving the Best CRO title four years in a row underscores NJ Bio’s position as the partner of choice in ADC development and inspires the team to elevate its standards even further in the coming year.